Amr Ragab

Menoufia, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

MASLD versus MAFLD in lean steatotic liver disease: diagnostic overlap, inclusivity, and the metabolically healthy lean phenotype.

MASLD versus MAFLD in lean steatotic liver disease: diagnostic overlap, inclusivity, and the metabolically healthy lean phenotype.

Journal: Clinical and experimental medicine

Published: October 18, 2025

Frailty and liver transplant eligibility beyond MELD scores: integrating functional status into candidate selection.

Frailty and liver transplant eligibility beyond MELD scores: integrating functional status into candidate selection.

Journal: BMC gastroenterology

Published: July 21, 2025

Sarcopenic visceral obesity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Sarcopenic visceral obesity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Journal: Clinical and experimental medicine

Published: July 17, 2025

ALBI-sarcopenia score as a predictor of treatment outcomes in hepatocellular carcinoma.

ALBI-sarcopenia score as a predictor of treatment outcomes in hepatocellular carcinoma.

Journal: Scientific reports

Published: December 26, 2024

Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis.

Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis.

Journal: European journal of gastroenterology & hepatology

Published: July 08, 2024

Appraisal of a newly developed ALBI-sarcopenia score as a prognostic marker in patients with hepatocellular carcinoma.

Appraisal of a newly developed ALBI-sarcopenia score as a prognostic marker in patients with hepatocellular carcinoma.

Journal: European journal of gastroenterology & hepatology

Published: April 16, 2024

Optimizing Prognostic Precision in Hepatocellular Carcinoma: Integrating PWR with ALBI and PALPI Scores.

Optimizing Prognostic Precision in Hepatocellular Carcinoma: Integrating PWR with ALBI and PALPI Scores.

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: February 29, 2024

Reply to: "correspondence about "Efficacy and safety of basiliximab".

Reply to: "correspondence about "Efficacy and safety of basiliximab".

Journal: Annals of hepatology

Published: January 21, 2022

Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study.

Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study.

Journal: Annals of hepatology

Published: August 10, 2020

MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation.

MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation.

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: July 02, 2020

Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.

Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: June 21, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026